Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karina Watts

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
PLOS Mental Health|April 29, 2026
An economic model to assess the costs and benefits of workplace mental wellbeing interventions: A flexible tool for employers and decision makersKarina Watts, Hannah Ross, Emily Gregg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2025
Economic Evaluation Results Are Substantially Affected by Parameter Input CorrelationErin Barker, Harriet Fewster, Karina Watts, et al.
Infectious Diseases and Therapy|April 19, 2025
An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service SettingMondher Toumi, Ruth Pulikottil-Jacob, Karina Watts, et al.
Pharmacoeconomics|August 7, 2025
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCLSam Harper, Daniela Afonso, Karina Watts, et al.
Jac-Antimicrobial Resistance|February 20, 2025
Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspectiveEmily Gregg, Sara Graziadio, William Green, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
PLOS Mental Health|April 29, 2026
An economic model to assess the costs and benefits of workplace mental wellbeing interventions: A flexible tool for employers and decision makersKarina Watts, Hannah Ross, Emily Gregg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2025
Economic Evaluation Results Are Substantially Affected by Parameter Input CorrelationErin Barker, Harriet Fewster, Karina Watts, et al.
Infectious Diseases and Therapy|April 19, 2025
An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service SettingMondher Toumi, Ruth Pulikottil-Jacob, Karina Watts, et al.
Pharmacoeconomics|August 7, 2025
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCLSam Harper, Daniela Afonso, Karina Watts, et al.
Jac-Antimicrobial Resistance|February 20, 2025
Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspectiveEmily Gregg, Sara Graziadio, William Green, et al.
Pageof 1